Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Fitzgerald, Kevin, Frank-Kamenetsky, Maria, Shulga-Morskaya, Svetlana, Liebow, Abigail, Bettencourt, Brian R, Sutherland, Jessica E, Hutabarat, Renta M, Clausen, Valerie A, Karsten, Verena, Cehelsky, Jeffrey, Nochur, Saraswathy V, Kotelianski, Victor, Horton, Jay, Mant, Timothy, Chiesa, Joseph, Ritter, James, Munisamy, Malathy, Vaishnaw, Akshay K, Gollob, Jared A, Simon, Amy
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387547/
https://ncbi.nlm.nih.gov/pubmed/24094767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(13)61914-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados